Yeah well the Sponsor can write whatever they want in their application. Doesn’t make it so. Clearly the agenda they are pushing now is that it doesn’t prevent infection or spread of the disease. And we can see that on the news with vaccinated people testing positive from olympians to sports teams to celebrities to these nursing home people; restaurants are closing again around my town (of their own choice) because vaxxed staff have tested positive.
And now look at this link below. I saw some of the early trial data reviews and they showed that the vaccine’s first shot work really good (aside from whatever side/after effects they may create) for about 5 weeks. Then their efficacy starts to drop. I presume that is why they made it a 2-dose regimen. But now, they are saying even after 2 doses, 10 weeks it drops from the purported 95% to 50%. 2nd shot doesn’t appear to add any additional value to the immune system except maybe a few extra weeks of good protection.
“UK scientists back Covid boosters as study finds post-jab falls in antibodies”
The terms of the EUA do though.
FACT SHEET FOR RECIPIENTS AND CAREGIVERS EMERGENCY USE AUTHORIZATION (EUA) OF THE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIVIDUALS 12 YEARS OF AGE AND OLDER...
WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)? The United States FDA has made the Pfizer-BioNTech COVID-19 Vaccine available under an emergency access mechanism called an EUA. The EUA is supported by a Secretary of Health and Human Services (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic.
The Pfizer-BioNTech COVID-19 Vaccine has not undergone the same type of review as an FDA-approved or cleared product. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, available alternatives. In addition, the FDA decision is based on the totality of scientific evidence available showing that the product may be effective to prevent COVID-19 during the COVID-19 pandemic and that the known and potential benefits of the product outweigh the known and potential risks of the product. All of these criteria must be met to allow for the product to be used in the treatment of patients during the COVID-19 pandemic.
The EUA for the Pfizer-BioNTech COVID-19 Vaccine is in effect for the duration of the COVID-19 EUA declaration justifying emergency use of these products, unless terminated or revoked (after which the products may no longer be used).
Moderna's EUA:
"Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of Moderna COVID-19 Vaccine for the prevention of COVID-19"
Janssens's EUA:
"On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for emergency use of the Janssen COVID-19 Vaccine for the prevention of COVID-19 for individuals 18 years of age and older pursuant to Section 564 of the Act."
Regarding this story here, there was a 90+% failure rate for the vaccine(s) to "prevent" COVID.
Now, of course, this is a single story. However, there is growing evidence being "leaked" through the governments firewall, that these "breakthrough" cases of fully vaccinated people getting COVID are increasing.
If this were about legitimate science...and not political science, those EUA's would be "revoked."
And, as for the UK:
“The JCVI (Joint Committee on Vaccination and Immunisation) is not currently advising routine vaccination of children outside of these groups (w/underlying health conditions), based on the current evidence.
As evidence shows that COVID-19 rarely causes severe disease in children without underlying health conditions, at this time the JCVI’s view is that the minimal health benefits of offering universal COVID-19 vaccination to children do not outweigh the potential risks.”
https://www.gov.uk/government/news/jcvi-issues-advice-on-covid-19-vaccination-of-children-and-young-people
A story here, by PBS: